(S)-nadifloxacin is a nadifloxacin. It is an enantiomer of a (R)-nadifloxacin. Levonadifloxacin is under investigation in clinical trial NCT03405064 (Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)). It is grouped under the following drug class(es): Fluoroquinolones, Quinolones and Topoisomerase inhibitors. Its therapeutic use is listed as antibacterials. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include levonadifloxacino and levonadifloxacinum. Its PubChem CID is 9850038.
Levonadifloxacin
| CAS No | 154357-42-3 |
|---|---|
| Molecular Formula | C19H21FN2O4 |
| Molecular Weight | 360.40 g/mol |
| Synonyms | (12S)-7-fluoro-8-(4-hydroxypiperidin-1-yl)-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
(S)-nadifloxacin is a nadifloxacin. It is an enantiomer of a (R)-nadifloxacin. Levonadifloxacin is under investigation in clinical trial NCT03405064 (Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)).
The listed CAS number is 154357-42-3.
The listed molecular formula is C19H21FN2O4.
The listed molecular weight is 360.40 g/mol.
(12S)-7-fluoro-8-(4-hydroxypiperidin-1-yl)-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid.
The source lists levonadifloxacino and levonadifloxacinum.